	US 11,718,684 B2
	Antibody binding specifically to MUC1 and use thereof
Kyung Duk Moon, Daejeon (KR); and Ho Il Choi, Daejeon (KR)
Assigned to PEPTRON, INC., Daejeon (KR)
Filed by PEPTRON, INC., Daejeon (KR)
Filed on Dec. 9, 2020, as Appl. No. 17/116,265.
Application 17/116,265 is a division of application No. 16/495,373, granted, now 11,472,887, previously published as PCT/KR2018/003267, filed on Mar. 21, 2018.
Claims priority of application No. 10-2017-0035622 (KR), filed on Mar. 21, 2017; and application No. 10-2018-0032592 (KR), filed on Mar. 21, 2018.
Prior Publication US 2021/0115153 A1, Apr. 22, 2021
Int. Cl. C07K 16/30 (2006.01); A61K 47/65 (2017.01); A61K 47/68 (2017.01); C12N 15/62 (2006.01); G01N 33/574 (2006.01); C12N 5/16 (2006.01)

CPC C07K 16/3092 (2013.01) [A61K 47/65 (2017.08); A61K 47/6851 (2017.08); C12N 15/62 (2013.01); G01N 33/574 (2013.01); C07K 2317/34 (2013.01); C12N 5/16 (2013.01)]

10 Claims

1. An antibody-drug conjugate in which a drug is conjugated with an anti-MUC1 antibody or an antigen-binding fragment thereof,

wherein the anti-MUC1 antibody or the antigen-binding fragment thereof recognizes a polypeptide comprising at least five consecutive amino acids in a C-terminal extracellular domain of MUC1,

wherein the anti-MUC1 antibody or the antigen-binding fragment thereof comprises:

a heavy-chain CDR1 of SEQ ID NO: 1; heavy-chain CDR2 of SEQ ID NO: 2; and heavy-chain CDR3 of SEQ ID NO: 3; and

a light-chain CDR1 of SEQ ID NO: 4; light-chain CDR2 of SEQ ID NO: 5; and light-chain CDR3 of SEQ ID NO: 6.